Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC) took place on the 8th-12th of November 2022 in Boston, MA, and virtually. Leading experts discussed practice-changing trial updates and the latest news in immuno-oncology!
View all videos

SITC 2022

Society for Immunotherapy of Cancer 37th Annual Meeting
08–12 November 2022 | Boston, MA
VJOncology avatar; VJ Oncology @VJOncology ·
April 19, 2024 1781291779913826750

Missing #AACR24? 🧬

…us too!

For exclusive coverage, interviews and all the latest in #Oncology visit us at 👉 http://VJOncology.com 👈

@AACR #oncology

Image for the Tweet beginning: Missing #AACR24? 🧬 …us too! For exclusive Twitter feed image.
Reply on Twitter 1781291779913826750 Retweet on Twitter 1781291779913826750 0 Like on Twitter 1781291779913826750 0 Twitter 1781291779913826750
VJOncology avatar; VJ Oncology @VJOncology ·
April 18, 2024 1780980922059264126

🎥We had the privilege of talking to @CharlesSwanton on the #BTOG24 keynote lecture surrounding the initiation of #lungcancer in response to the inhalation of air pollution

👀Interview coming soon to http://VJOncology.com - watch this space!

@BTOGORG #LCSM #NSCLC @TheCrick

Image for the Tweet beginning: 🎥We had the privilege of Twitter feed image.
Reply on Twitter 1780980922059264126 Retweet on Twitter 1780980922059264126 2 Like on Twitter 1780980922059264126 14 Twitter 1780980922059264126
VJOncology avatar; VJ Oncology @VJOncology ·
April 18, 2024 1780967192143536202

🎥We were delighted to catch up with @cpeedell on #lungcancer updates at #BTOG24 including whether there is a role for radiotherapy in extensive-stage #SCLC

👉Full interview coming soon to http://VJOncology.com

@BTOGORG #LCSM #NSCLC #LungCancer

Image for the Tweet beginning: 🎥We were delighted to catch Twitter feed image.
Reply on Twitter 1780967192143536202 Retweet on Twitter 1780967192143536202 3 Like on Twitter 1780967192143536202 6 Twitter 1780967192143536202
VJOncology avatar; VJ Oncology @VJOncology ·
April 18, 2024 1780906710992842782

🎥We had the pleasure of catching up with @AdamJanuszewski this morning to discuss the BTOG Therapeutics Symposium, ADCs in #lungcancer, and more at #BTOG24

👀Interview coming soon to http://VJOncology.com

@BTOGORG #LCSM #NSCLC #SCLC #LungCancer

Image for the Tweet beginning: 🎥We had the pleasure of Twitter feed image.
Reply on Twitter 1780906710992842782 Retweet on Twitter 1780906710992842782 2 Like on Twitter 1780906710992842782 4 Twitter 1780906710992842782
Load More

SITC 2022

Society for Immunotherapy of Cancer 37th Annual Meeting
08–12 November 2022 | Boston, MA
The 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC) took place on the 8th-12th of November 2022 in Boston, MA, and virtually. Leading experts discussed practice-changing trial updates and the latest news in immuno-oncology!
View all videos
VJOncology avatar; VJ Oncology @VJOncology ·
April 19, 2024 1781291779913826750

Missing #AACR24? 🧬

…us too!

For exclusive coverage, interviews and all the latest in #Oncology visit us at 👉 http://VJOncology.com 👈

@AACR #oncology

Image for the Tweet beginning: Missing #AACR24? 🧬 …us too! For exclusive Twitter feed image.
Reply on Twitter 1781291779913826750 Retweet on Twitter 1781291779913826750 0 Like on Twitter 1781291779913826750 0 Twitter 1781291779913826750
VJOncology avatar; VJ Oncology @VJOncology ·
April 18, 2024 1780980922059264126

🎥We had the privilege of talking to @CharlesSwanton on the #BTOG24 keynote lecture surrounding the initiation of #lungcancer in response to the inhalation of air pollution

👀Interview coming soon to http://VJOncology.com - watch this space!

@BTOGORG #LCSM #NSCLC @TheCrick

Image for the Tweet beginning: 🎥We had the privilege of Twitter feed image.
Reply on Twitter 1780980922059264126 Retweet on Twitter 1780980922059264126 2 Like on Twitter 1780980922059264126 14 Twitter 1780980922059264126
VJOncology avatar; VJ Oncology @VJOncology ·
April 18, 2024 1780967192143536202

🎥We were delighted to catch up with @cpeedell on #lungcancer updates at #BTOG24 including whether there is a role for radiotherapy in extensive-stage #SCLC

👉Full interview coming soon to http://VJOncology.com

@BTOGORG #LCSM #NSCLC #LungCancer

Image for the Tweet beginning: 🎥We were delighted to catch Twitter feed image.
Reply on Twitter 1780967192143536202 Retweet on Twitter 1780967192143536202 3 Like on Twitter 1780967192143536202 6 Twitter 1780967192143536202
VJOncology avatar; VJ Oncology @VJOncology ·
April 18, 2024 1780906710992842782

🎥We had the pleasure of catching up with @AdamJanuszewski this morning to discuss the BTOG Therapeutics Symposium, ADCs in #lungcancer, and more at #BTOG24

👀Interview coming soon to http://VJOncology.com

@BTOGORG #LCSM #NSCLC #SCLC #LungCancer

Image for the Tweet beginning: 🎥We had the pleasure of Twitter feed image.
Reply on Twitter 1780906710992842782 Retweet on Twitter 1780906710992842782 2 Like on Twitter 1780906710992842782 4 Twitter 1780906710992842782
Load More

Latest videos from SITC 2022!

View all videos
1:21
Ultra-pH sensitive nanoparticles increasing therapeutic index of IL-2-Fc
Jinming Gao • 1 Nov 2022
0:45
ONM-405: pH activated nanoparticle for activating NK- and T-cells in solid tumors
Jinming Gao • 1 Nov 2022
4:37
Treating PD-L1-positive NSCLC with immunotherapy alone vs chemoimmunotherapy
Biagio Ricciuti • 17 Nov 2022
6:26
Acquired mechanisms of resistance to PD-(L)1 blockade in NSCLC
Biagio Ricciuti • 17 Nov 2022

Lung Cancer at SITC 2022!

View all
4:37
Treating PD-L1-positive NSCLC with immunotherapy alone vs chemoimmunotherapy
Biagio Ricciuti • 17 Nov 2022
6:26
Acquired mechanisms of resistance to PD-(L)1 blockade in NSCLC
Biagio Ricciuti • 17 Nov 2022
4:39
Tmod cellular logic gate as a solution to on-target, off-tumor toxicity in CAR-T for solid tumors
J. Randolph Hecht • 15 Nov 2022
4:35
Neoadjuvant checkpoint inhibition in NSCLC
Biagio Ricciuti • 17 Nov 2022

Skin Cancer at SITC 2022!

View all
2:01
Developing novel T-cell therapeutics for patients with melanoma who do not respond to ICI’s
Cristina Puig Saus • 31 Oct 2022
2:16
Landscape analysis of neoepitope-specific T-cell responses depending on clinical benefit from ICIs
Cristina Puig Saus • 31 Oct 2022
2:58
Results of a Phase II trial of vidutolimod and nivolumab in melanoma
Diwakar Davar • 7 Nov 2022
4:17
Microbiome modification with fecal transplant before IO to reduce primary resistance in melanoma
Saman Maleki • 2 Nov 2022

Antibodies at SITC 2022!

View all
4:17
Microbiome modification with fecal transplant before IO to reduce primary resistance in melanoma
Saman Maleki • 2 Nov 2022
5:15
Combination myeloid cell and T-cell targeting as an effective anti-tumor strategy
Judith Varner • 3 Nov 2022
4:27
Key updates in immunotherapies for melanoma
Diwakar Davar • 7 Nov 2022
1:20
Pixatimod and nivolumab in metastatic melanoma, NSCLC and MSS CRC
Diwakar Davar • 7 Nov 2022

Checkpoint Inhibitors at SITC 2022!

View all
4:37
Treating PD-L1-positive NSCLC with immunotherapy alone vs chemoimmunotherapy
Biagio Ricciuti • 17 Nov 2022
6:26
Acquired mechanisms of resistance to PD-(L)1 blockade in NSCLC
Biagio Ricciuti • 17 Nov 2022
0:21
Identifying and managing patients who develop ICI-associated acute kidney injury
Shruti Gupta • 16 Nov 2022
0:59
Remaining challenges in the field of onco-nephrology
Shruti Gupta • 16 Nov 2022
The content of VJOncology is intended for healthcare professionals